Core Services
Non-dilutive Funding

LBG consultants have the insight, knowledge, and network to match your program with the appropriate government agency and/or opportunities, and employs a unique business model to help navigate the process.
Learn MoreProduct Development

LBG consultants have years of experience across all functional product development disciplines for vaccines, therapeutics, cell and gene therapies, and medical devices and diagnostics; and can provide on-demand expertise and advice at strategic crossroads or as a full-fledged product development team.
Learn MoreStrategic Consulting

LBG consultants support pipeline and portfolio review and analysis, industry benchmarking, market research, asset opportunity and prioritization analysis, due diligence and financial modeling support among other things.
Learn MoreWe provide the depth of expertise necessary to advance your programs, by offering a range of life science services supporting vaccine, therapeutic, medical device and diagnostic product development.


Our Expertise
With proven expertise across a wide spectrum of life science products and sectors, LBG is equipped to deliver effective development and funding solutions for your specific needs. From vaccines to cell & gene therapies to diagnostics to animal health products, we have the depth of expertise to plug into your teams and provide the right guidance and support to help you reach your organizational objectives.
Product and sector expertise include:
- Cell & Gene Therapy
- Vaccine Development
- Therapeutic Products
- Non-Dilutive Funding
- Program Management
- Business Development
Recent News
View More NewsLBG Engages with Thought Leaders and Experts to Advance Global Biotech Industry
Therapeutic frontiers, the business of biotech, regulatory and policy outlooks, and human capital are just a few of the trending topics of discussion at the BIO International Convention. LBG Partners …
Read MoreJim Beltzer and Joe Rininger Join Effort to Transform Medicine Through the Use of Cell and Gene Therapies
The record number of gene, gene-modified cell therapies since last year and the recent approval of Gamida Cell’s Omisirge off-the-shelf allogeneic therapy raises an important question: How are other advanced …
Read More